Posted by Michael Wonder on 29 Mar 2021
Rocket Pharmaceuticals receives EMA Priority Medicines (PRIME) designation for RP-L201 gene therapy for treatment of leukocyte adhesion deficiency-I
29 March 2021 - LAD-I program now holds all available accelerated regulatory designations in the U.S. and EU.
Rocket Pharmaceuticals today announces that the EMA has granted Priority Medicines (PRIME) designation to RP-L201, the Company’s investigational gene therapy for leukocyte adhesion deficiency-I.
PRIME designation was granted based on encouraging preliminary safety and efficacy data from the ongoing Phase 1/2 clinical trial of RP-L201.
